Clinical and cardiac imaging in bosentan treatment for pulmonary arterial hypertensio

Not Applicable

Recruiting

• Conditions: Diseases of the circulatory system

• Registration Number: KCT0001530
• Lead Sponsor: The Catholic University of Korea, Seoul St. Mary's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 March 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

WHO group 1 pulmonary arterial hypertension (PAH) patients with
(1) naive to endothelin receptor blocker (ETRB) patients, or; (2) previous ETRB treatment interrupted >30 days

Exclusion Criteria

Patients who cannot 6 minute walk test, contraindication to bosentan, significant arrhythmia impairing adequate ECG-gated cardiac CT imaging, contraindication to CT contrast dye, active malignancy, expected survival <1 year from any cause, failure to obtain informed consent

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
6 minute walk distance

Secondary Outcome Measures

Name	Time	Method
Clinical symptom, laboratory, cardiac CT findings